Literature DB >> 21056671

Population pharmacokinetics of mycophenolic acid in pediatric renal transplant patients using parametric and nonparametric approaches.

A Prémaud1, L T Weber, B Tönshoff, V W Armstrong, M Oellerich, S Urien, P Marquet, A Rousseau.   

Abstract

Mycophenolic acid (MPA) is an immunosuppressive drug widely used in the prevention of acute rejection in pediatric renal transplant recipients and is characterized by a wide inter-individual variability in its pharmacokinetics. The aim of this study was to compare population pharmacokinetic modeling of MPA in pediatric renal transplant recipients given mycophenolate mofetil, the ester prodrug of MPA, using parametric and nonparametric population methods. The data from 34 pediatric renal transplants (73 full pharmacokinetic profiles obtained on day 21, months 3, 6 and 9 post-transplant) were analyzed using both the nonlinear mixed-effect modeling (NONMEM) and nonparametric adaptive grid (NPAG) approaches, based on a two-compartment model with first order lagged time absorption and first order elimination. The predictive performance of the two models was evaluated in a separate group of 32 patients. Higher mean population parameter values and ranges of individual pharmacokinetic parameters were obtained with NPAG, especially for the elimination constant ke: mean 1.16 h(-1) (0.26-4.33 h(-1)) and 0.78 h(-1) (0.66-1.15 h(-1)) with NPAG and NONMEM, respectively. With NPAG, the skewness and kurtosis values for ke (2.03 and 7.80, respectively) were far from the theoretical values expected for normal distributions. Such a non-normal distribution could explain the high value of shrinkage (35%) obtained for this parameter with the parametric NONMEM method. Bayesian forecasting of mycophenolic acid exposure using the NPAG population pharmacokinetic parameters as priors yielded a better predictive performance, with a significantly smaller bias than with the NONMEM model (-1.68% vs -9.53%, p<0.0001). In conclusion, in the present study, NPAG was found to be the most adequate population pharmacokinetic method to describe the pharmacokinetics of MPA in pediatric renal transplant recipients.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21056671     DOI: 10.1016/j.phrs.2010.10.017

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  15 in total

1.  Population pharmacokinetics and Bayesian estimators for intravenous mycophenolate mofetil in haematopoietic stem cell transplant patients.

Authors:  Marc Labriffe; Julien Vaidie; Caroline Monchaud; Jean Debord; Pascal Turlure; Stephane Girault; Pierre Marquet; Jean-Baptiste Woillard
Journal:  Br J Clin Pharmacol       Date:  2020-02-28       Impact factor: 4.335

Review 2.  Therapeutic drug monitoring in pediatric renal transplantation.

Authors:  Lutz T Weber
Journal:  Pediatr Nephrol       Date:  2014-04-25       Impact factor: 3.714

3.  Population pharmacokinetic model and Bayesian estimator for 2 tacrolimus formulations in adult liver transplant patients.

Authors:  Camille Riff; Jean Debord; Caroline Monchaud; Pierre Marquet; Jean-Baptiste Woillard
Journal:  Br J Clin Pharmacol       Date:  2019-06-14       Impact factor: 4.335

4.  Comment on "Population Pharmacokinetics of Mycophenolic Acid: An Update".

Authors:  Jean-Baptiste Woillard; Jean Debord; Pierre Marquet
Journal:  Clin Pharmacokinet       Date:  2018-09       Impact factor: 6.447

Review 5.  Some comments and suggestions concerning population pharmacokinetic modeling, especially of digoxin, and its relation to clinical therapy.

Authors:  Roger W Jelliffe
Journal:  Ther Drug Monit       Date:  2012-08       Impact factor: 3.681

6.  Can Population Pharmacokinetics of Antibiotics be Extrapolated? Implications of External Evaluations.

Authors:  Yu Cheng; Chen-Yu Wang; Zi-Ran Li; Yan Pan; Mao-Bai Liu; Zheng Jiao
Journal:  Clin Pharmacokinet       Date:  2021-01       Impact factor: 6.447

7.  A multiple methods approach to determine adherence with prescribed mycophenolate in children with kidney transplant.

Authors:  Reham Almardini; Esra' O Taybeh; Mervat M Alsous; Ahmed F Hawwa; Karl McKeever; Rob Horne; James C McElnay
Journal:  Br J Clin Pharmacol       Date:  2019-05-11       Impact factor: 4.335

Review 8.  How accurate and precise are limited sampling strategies in estimating exposure to mycophenolic acid in people with autoimmune disease?

Authors:  Azrin N Abd Rahman; Susan E Tett; Christine E Staatz
Journal:  Clin Pharmacokinet       Date:  2014-03       Impact factor: 6.447

9.  Population Pharmacokinetics of Mycophenolic Acid: An Update.

Authors:  Tony K L Kiang; Mary H H Ensom
Journal:  Clin Pharmacokinet       Date:  2018-05       Impact factor: 6.447

10.  Pharmacokinetics of Vancomycin in Elderly Patients Aged over 80 Years.

Authors:  Laurent Bourguignon; Yoann Cazaubon; Guillaume Debeurme; Constance Loue; Michel Ducher; Sylvain Goutelle
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.